Literature DB >> 20078490

Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.

Adam R Winstock1, Toby Lea, Janie Sheridan.   

Abstract

AIMS: To explore service provision and the range of problems that New South Wales (NSW) and Victoria (VIC) community pharmacists providing opioid substitution treatment (OST) have experienced with clients and prescribers.
DESIGN: ross-sectional postal survey.
SETTING: All community pharmacies providing OST in NSW (n = 593) and VIC (n = 393), Australia. PARTICIPANTS: Completed questionnaires were received from 669 pharmacists (68% response rate). MEASUREMENTS: The questionnaire addressed pharmacy characteristics, recent problems experienced with clients including refusal to dose, provision of credit for dispensing fees, termination of treatment, responses of pharmacists to problems experienced with clients, as well as problems experienced with OST prescribers.
FINDINGS: In the preceding month, 41% of pharmacists had refused to dose a client for any reason, due most commonly to expired prescriptions (29%), or > or issed doses (23%). Terminating a client's treatment in the past month was reported among 14% of respondents, due most commonly to inappropriate behaviour and missed doses. Treatment termination was reported by a significantly higher proportion of pharmacists in VIC (P < 0.001). Treatment termination in last month was predicted having more clients (P < 0.001), the provision of buprenorphine treatment (P = 0.008), having a separate dosing area (P = 0.021), and being a female pharmacist (P = 0.013). Past month refusal to dose was predicted by the pharmacy being in VIC (P < 0.001) and having more clients (P < 0.001). Problems experienced most commonly in the past month with prescribers were difficulty contacting prescriber (21%) and provision of takeaway doses to clients considered unstable by the pharmacist (19%) (higher in VIC: both P < 0.001).
CONCLUSIONS: This study highlights the range of problems experienced by community pharmacists in the delivery of OST and the consequences for people in treatment. Particular attention should be focused upon considering number of clients per pharmacy and improving professional communication between pharmacists and prescribers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20078490     DOI: 10.1111/j.1360-0443.2009.02774.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  8 in total

1.  Communication Experiences of DATA-Waivered Physicians with Community Pharmacists: A Qualitative Study.

Authors:  Daniel J Ventricelli; Stephanie M Mathis; Kelly N Foster; Robert P Pack; Fred Tudiver; Nicholas E Hagemeier
Journal:  Subst Use Misuse       Date:  2019-10-08       Impact factor: 2.164

2.  Provision of opioid substitution therapy services in Australian pharmacies.

Authors:  B B Chaar; J R Hanrahan; C Day
Journal:  Australas Med J       Date:  2011-04-30

3.  Australian Community Pharmacy Harm-Minimisation Services: Scope for Service Expansion to Improve Healthcare Access.

Authors:  Sara S McMillan; Hidy Chan; Laetitia H Hattingh
Journal:  Pharmacy (Basel)       Date:  2021-04-26

4.  The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives.

Authors:  Sami Isaac; Bandana Saini; Betty B Chaar
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

5.  Implementing a clozapine supply service in Australian community pharmacies: barriers and facilitators.

Authors:  Bethany Wilson; Sara S McMillan; Amanda J Wheeler
Journal:  J Pharm Policy Pract       Date:  2019-08-07

6.  Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.

Authors:  Paxton Bach; Daniel Hartung
Journal:  Addict Sci Clin Pract       Date:  2019-09-02

7.  The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study.

Authors:  Alexandra Shepherd; Bianca Perrella; Hendrika Laetitia Hattingh
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-08-10

8.  Community pharmacists' experiences in mental illness and addictions care: a qualitative study.

Authors:  Andrea L Murphy; Heather Phelan; Scott Haslam; Ruth Martin-Misener; Stan P Kutcher; David M Gardner
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-01-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.